Efficacy of the laser at low intensity on primary burning oral syndrome: a systematic review

Ana Liz Pereira de Matos 1, Pedro Urquiza Jayme Silva 2, Luiz Renato Paranhos 3, Ingrede Tatiane Serafim Santana 4, Felipe Rodrigues de Matos 5

1 Postgraduate Program in Sciences Applied to Health. Federal University of Sergipe, Lagarto / SE, Brazil
2 Department of oral and maxillofacial pathology. Federal University of Uberlândia / MG, Brazil
3 Department of Social and Preventive Dentistry. Federal University of Uberlândia / MG, Brazil
4 Postgraduate Program in Physiological Sciences. Federal University of Sergipe, São Cristóvão / SE, Brazil
5 Department of Dentistry. Federal University of Sergipe, Lagarto / SE, Brazil

Correspondence:
Department of Dentistry
Avenida Governador Marcelo Deda, 300
Postal Code 49400-000. São José Lizard, Lagarto (SE). Brazil
felipeodonto@gmail.com

Received: 08/07/2020
Accepted: 07/01/2021

Abstract
Background: Primary burning mouth syndrome (BMS) is a chronic clinical condition of idiopathic mainly characterized by pain and a burning sensation in the oral cavity. The application of laser at low intensity therapy is a treatment option. This systematic review evaluated the efficacy of laser therapy in treating symptoms of burning mouth syndrome.

Material and Methods: The study was formulated according to the PRISMA and Cochrane guidelines. Seven databases were used as primary sources of research. Only randomized controlled clinical trials were included. The efficacy of the therapy was estimated comparing the values of the visual and numerical scales of pain before and after laser treatment, through qualitative analysis.

Results: The search resulted in 348 records and only eight filled the eligibility criteria and were included. All studies evaluated pain and / or a burning sensation considering a time interval of two to ten weeks. The total sample consisted of 314 patients submitted to treatment: 123 from the control group, who participated with laser off or with the tip blocked, and 191 from the intervention group, treated with low-level laser therapy. The female gender stood out and the average age of the participants was 60.89 years. The main symptoms reported were pain and a burning sensation in the oral mucosa and tongue. The parameters adopted by the authors for laser treatment were diverse and the variables were not fully described in the published studies. Visual analog and numerical scales were used to assess symptoms and only three studies showed statistical significance.

Conclusions: It is suggested that laser therapy may be an effective alternative in the treatment of BMS. New randomized clinical trials should consider well-established protocols to better understand the efficacy of laser therapy without confounding the effects.

Key words: Efficacy, systematic review, burning mouth syndrome, low level laser therapy.
Introduction
The Burning Mouth Syndrome (BMS) is mainly a chronic medical condition, idioptic characterized by pain with burning sensation in the oral cavity without any dysfunction and apparent or detectable organic cause (1). The epidemiology of BMS is not fully known, having a high occurrence in postmenopausal women (2,3). The general prevalence is still unreliable due to the large variation in published studies (0.01% to 40%), with a tendency to increase with advancing age (4).

BMS has a complex pathogenesis involving psychogenic factors and deregulated peripheral and central pain, not existing a standard treatment protocol for management (5). The diagnosis of all symptoms in each patient of BMS must be analyzed meticulously and carefully. It is diagnosed by exclusion and it has among others, topical and systemic treatments, seeking the decrease of the symptoms (6).

The low intensity laser therapy (or biomodulation) is an alternative for the treatment of symptoms of BMS. The low intensity laser (LLLT) is the application of light with a low power laser or LED that promotes tissue regeneration, reduces inflammation and relieves pain (7). There is no thermal effects and analgesia in LLLT are brought beneficial results with reduced pain and symptoms (6).

There is evidence that points to the influence of local cytokine levels, growth factors, inflammatory mediators and increases tissue oxygenation (10). When mitochondria meets the light, the cytochrome c oxidase increases the production of adenosine triphosphate (ATP) by phosphorylation oxidative. In addition, it modulates reactive oxygen species and induces transcription factors (8). These effects, in turn, lead to cell proliferation and migration (particularly by fibroblasts), also lead to modulation in cytokine levels, growth factors, inflammatory mediators and increases tissue oxygenation (10).

Researchers defend the primary role of low intensity light in mitochondria (8,10). When mitochondria meets the light, the cytochrome c oxidase increases the production of adenosine triphosphate (ATP) by phosphorylation oxidative. In addition, it modulates reactive oxygen species and induces transcription factors (8). These effects, in turn, lead to cell proliferation and migration (particularly by fibroblasts), also lead to modulation in cytokine levels, growth factors, inflammatory mediators and increases tissue oxygenation (10).

Until then, the literature presents controversial results on the effectiveness of low-level laser therapy in Burning Mouth Syndrome, by comparing the reduction of pain symptoms and burning sensation. Clinical trials have brought beneficial results with reduced pain and burning sensation in patients with BMS treated with LLLT (11-13), while another trial concluded that both LLLT and placebo reduced the symptoms of BMS (14).

There is evidence that points to the influence of local inflammatory processes in the oral cavity and systemic in association with the pathophysiology of BMS. Inflamed tissues produce more reactive oxygen species - a by-product of inflammation, which compromises the production of ATP in cells. The production of nitric oxide (NO) in the mitochondria in cases of injury, such as inflammation, can inhibit as mitochondrial airways, as NO is reversibly bound to cytochrome c oxidase, an essential enzyme in this airway. The low intensity laser, in turn, can reverse this bond between NO and cytochrome c oxidase by changing the redox potential of the cell, allowing it to produce ATP and accelerate the process of repairing the inflammatory reaction, improving the symptomatic condition of BMS (15).

Before the exposed controversy, the aim of this study is to evaluate the effectiveness of therapy of low-level laser therapy in the treatment of symptoms of Burning Mouth Syndrome primary through a systematic review of current literature.

Material and Methods
- Protocol and registration
This systematic review was carried out in accordance with the recommendations of PRISMA (preferred reporting items for systematic analyzes and meta-analyzes) (16) and the Cochrane guidelines (17). The systematic review protocol was registered in the PROSPERO database (CRD42021226064).

- Study design and eligibility criteria
This study was a systematic review based on the PICO strategy, in order to answer the following question: “Is low-level laser therapy effective in reducing the symptoms of Burning Mouth Syndrome (BMS)?” For this purpose, the population was patients with primary Burning Mouth Syndrome; intervention - low intensity laser therapy; Patients were compared with Primary Burning Mouth Syndrome treated with Laser low intensity therapy versus placebo - and as a conclusion, the patients’ pain and a burning sensation in the oral cavity decreased.

The inclusion criteria were randomized clinical trials, with no period restriction, published in any language, which dealt with the evaluation of the effectiveness of low-level laser therapy in the treatment of the symptoms of Burning Mouth Syndrome. The exclusion criteria were studies outside the scope of this systematic review, in vitro studies, performed on animals, case reports, letter to the editor and / or editorials, literature review, books and book chapters, pilot study and indexes and abstracts or university work assignment with insufficient data (letters, personal opinions, conference abstracts).

- Sources of information and research
All steps were taken to minimize the biases of selection and publication. The base data PubMed (including Medline), Scopus, Embase, SciELO, Web of Science, Latin-American and Caribbean Health Sciences (LILACS) and Cochrane were used as primary sources of

e217
study. The OpenGrey and Open Access (OATD) theses and dissertations were used to access the "gray literature" to avoid bias in relation to the lack of published negative results.

The resources MeSH (Medical Subject Headings), DeCS (Health Sciences Descriptors) and Emtree (Embase Subject Headings) were used to select the search descriptors. The Boolean operators “AND” and “OR” were used to improve the search strategy through various combinations.

The first bibliographic search was carried in April 2020. The results obtained were imported into EndNote Web™ software (Thomson Reuters, Toronto, Canada) to remove duplicates. The rest of the results were imported into Microsoft Word™ 2010 (Microsoft™ Ltd, Washington, USA), in which the remaining duplicates were removed manually.

- Study selection
  Two independent reviewers [ALPM and PJU] were previously calibrated on a sample of 20% of the studies and reached an appropriate agreement between the examiners. The eligibility review was carried out independently by these reviewers, with disagreements resolved by discussion with a third reviewer [LRP] to reach consensus. The selection of studies was carried out in two stages.

  - The first stage included a thorough analysis of the titles and abstracts of the articles. Reviewers were not blind to the names of authors and journals. Studies with titles unrelated to the topic of interest in our review were eliminated at this stage. The titles that met the objectives of our study, but had no abstracts available, were fully analyzed in the second stage.

  - In the last stage, the eligible studies had their full texts obtained and evaluated to verify whether they met the eligibility criteria. The references of the eligible articles were carefully evaluated to verify studies that were not detected in the main search strategy. The excluded studies were registered separately, together with the reasons for exclusion.

- Data collect
  After selection, the studies were analyzed by two reviewers [ALPM and PJU], who extracted the following information from the articles: identification (author, year, country and place of the research), characteristics of the sample (number of patients in each study, sex distribution, average age, laser parameters and pain analogue scale).

- Risk of individual study bias
  The Critical Assessment Tools of the Joanna Briggs Institute (JBI) for using in Systematic Reviews for Randomized Clinical Trials (18) were used to assess the risk of bias and the individual quality of the selected studies. Two authors [ALPM and PJU] independently assessed each domain in relation to the potential risk of bias, as recommended by the PRISMA statement (16). Each study was categorized according to the percentage of positive responses to the questions corresponding to the assessment instrument. The risk of bias was considered high when the study obtained 49% of the answers "yes", moderate or medium when the study obtained 50% to 69% of the answers "yes" and low when the study reached more than 70% of the score "yes".

- Data analysis
  The data collection process was carried out through analysis of the selected studies, and the conclusion was presented in a descriptive / narrative manner, analyzing the heterogeneity of the studies. A meta-analysis was planned if the data from the eligible studies were homogeneous.

**Results**

During the first phase of study selection, 348 papers were found. One study was found in the "gray literature", but it did not meet the objective and was removed manually. After removing duplicates, 203 papers remained for analysis of titles and abstracts. After a detailed analysis, only seven studies were eligible to review the full text.

The references of these eligible studies were carefully evaluated, and an additional article was selected. None of these seven studies were excluded for the purposes of qualitative analysis (review) Fig. 1. reproduces the process of searching, identifying, including and excluding articles. The studies were published between 2015 and 2020 and carried out in Spain (13,19,20), Brazil (12,14), Italy (21), Croatia (22) and Iran (11). The sources of information on the demographic and clinical characteristics of the population are available in Table 1.

All articles were approved by the Ethics Committee of the respective institution or hospital and reported that informed consent was obtained before the study started. Only two studies followed the CONSORT statement (11,19). Five of the eight eligible studies reported decrease in symptoms after application of therapy to laser. Two studies presented the registration number of their randomized controlled trial (11,19).

Two studies suggested the need for further research with established protocols and larger samples to determine the real effectiveness of laser therapy in BMS (21,22). Pedro et al. [2020] (19) pointed out the need furthermore also with longer follow - up and more sessions to assess the possibility of periodic application of therapy to laser.

The groups were allocated to part of the sample "group laser - irradiation received by infrared laser or red" and "control- group received no irradiation," the laser has been turned off or has been blocked end. Only one study (12) used red laser and two other groups with the same infrared laser in equal parameters, but with differences in treatment time.
Fig. 1: Flowchart of the literature search and selection process adapted from the PRISMA statement.

Table 1: General characteristics of the studies.

| Author        | Year | Country of origin | Ethical criteria | Informed consent | Participants | Average age | Gender | Race / Color |
|---------------|------|-------------------|------------------|------------------|--------------|-------------|--------|--------------|
| Arbabi-Kalati, et al. | 2015 | Iran              | Yes              | Yes              | 20 (LG: 10; CG: 10) | 46,9        | F: 20/M: 0 | NR           |
| Spanemberg et al. | 2015 | Brazil            | Yes              | Yes              | 78 (LG inf 1-20; LG inf 2-20; RLG: 19; CG: 19) | 62,82       | F: 67/M: 11 | NR           |
| Valenzuela, Lopez Jornet | 2016 | Spain             | Yes              | Yes              | 44 (LG inf 1-16; LG inf 2-16; CG: 12) | 65,5        | F: 41/M: 3 | NR           |
| Sugaya et al. | 2016 | Brazil            | Yes              | Yes              | 23 (LG: 13; CG: 10) | 59,7        | F: 21/M: 2 | NR           |
| Spanemberg et al. | 2019 | Spain             | Yes              | Yes              | 21 (LG: 12; CG: 9) | 66,5        | F: 20/M: 1 | NR           |
| Bardellini et al. | 2019 | Italy             | Yes              | Yes              | 85 (LG: 43; CG: 42) | 60,3        | F: 85/M: 0 | NR           |
| Skrinjar et al. | 2020 | Croatia           | Yes              | Yes              | 23 (LG: 12; CG: 11) | 61,5        | F: 20/M: 3 | NR           |
| Pedro et al. | 2020 | Spain             | Yes              | Yes              | 20 (LG: 10; CG: 10) | 63,95       | F: 16/M: 4 | NR           |

Legend: LG: laser group; CG: control group; RLG: red laser group; F: female; M: male; NR: not reported.
The study by Valenzuela and Lopez Jornet [2016] (13) used two groups with the infrared laser, but in different parameters. Table 2 summarizes the main characteristics of the eligible studies regarding the parameters used for therapy the laser.

As for the risk of bias, two studies were high risk and four studies were medium risk. Only two studies (19,21) had a low risk of bias. Table 3 presents these detailed results, assessed by the Joanna Briggs Institute (JBI) Critical Assessment Tools for use in Systematic Reviews for studies of randomized controlled trials (18).

Most studies used the Visual Analogical Scale (VAS) to assess pain and burning sensation in the participants. Arbabi-Kalati, Bakhshani and Rasti [2015] (11) used a numerical display scale (EVN) and Spanemberg et al. [2015] (12) used VAS and EVN. Seven studies considered scales with values from zero to ten (zero refers to no pain or burning sensation and ten intense pain and / or burning). Except Sugaya et al. [2016] (14) who considered zero to five. Table 4 shows the average VAS and EVN scores contained in the studies, in addition to the time of follow-up of treatment and their outcome.

Table 2: Summary of the main characteristics of the eligible studies.

| Author               | Laser Feature                                      | Wavelength (Nm) | Energy Fluence (J/cm²) | Power (Mw) | Power Density (W/cm²) | Duration Of Irradiation | Dose (J) | Spot Size (cm²) | Wave Frequency |
|----------------------|---------------------------------------------------|-----------------|------------------------|------------|------------------------|-------------------------|----------|-----------------|----------------|
| Arbabi-Kalati et al., 2015 | Mustange laser device diode-gallium-arsenide laser (Russia) | 630 nm | 1 J/cm² | 30 mW | NR | 10 seconds | 3 J | NR | NR |
| Spanemberg et al., 2015 | Diode laser (Thera Lase™, DMC Equipamentos LTDA.) | LG inf 1: 830 nm/ RLG: 685 nm | LG inf 1: 176 J/cm²/ RLG: 72 J/cm² | LG inf 1: 100 mW/ RLG: 35 mW | NR | LG inf 1: 50 seconds per point/ RLG: 58 seconds per point | LG inf 1: 3 J | LG inf 1: 0.028 cm² | LG inf 1 e LG inf 2: continuous |
| Valenzuela, Lopez Jornet, 2016 | LaserSmile®, Biolase Technology. Gallium and aluminium arsenide diode laser | LG inf 1 e LG inf 2: 815nm | LG inf 1: 133.3 J/cm²/ LG inf 2: 200 J/cm² | LG inf 1 e LG inf 2: 1 mW | NR | LG inf 1: 4 seconds LG inf 2: 6 seconds | LG inf 1: 6 J | LG inf 1 e LG inf 2: 0.03 cm² | LG inf 1 e LG inf 2: continuous |
| Sugaya et al., 2016 | Infrared diode laser - AsGaAl, model QTUMO0A / QUANTUM (Ecco Fibras Opticas e Dispositivos LTDA) | 790 nm | 6 J/cm² | 20 mW | 4 W/cm² | 50 seconds per point | 6 J | 0.03 cm² | continuous |
| Spanemberg et al., 2019 | Thor Laser®-gallium and aluminium arsenide diode laser | 808nm ±5nm | NR | 200 mW | 1.97 W/cm² | 15 seconds per point | 3 J | 0.088 cm² | continuous |
| Bardellini et al., 2019 | K Laser Cube 3® | 660-970 nm | NR | 3.2 mW (6.4 mW pulsed to 50%) | NR | 3 minutes e 51 seconds | NR | 1 cm² | continuous and pulsed |
| Skrinjar et al., 2020 | Ga-Al-As LED Laser Light | 685 nm | 60 J/cm² | 30 mW | 0.003 W/cm² | 381 seconds | 2 J | 3 cm² | NR |
| Pedro et al., 2020 | Diode Laser Fox (A.R.C. Laser, Italy) | 810 nm | 12 J/cm² | 60 mW | 1.2 W/cm² | 6 seconds per point in 56 points | 6 J | 0.5 cm² | continuous |

Legend: LG inf: laser group infra-red; RLG: red laser group; NR: not reported
Table 3: Risk of bias assessed by the Joanna Briggs Institute Critical Assessment Tools for use in JBI Systematic Reviews for studies of randomized clinical trials.

| Authors | Q.1 | Q.2 | Q.3 | Q.4 | Q.5 | Q.6 | Q.7 | Q.8 | Q.9 | Q.10 | Q.11 | Q.12 | Q.13 | % / risk |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----------|
| Arbabi-Kalati, Bakhshani e Rasti, 2015 | √   | N/A | U   | √   | U   | √   | √   | N/A | √   | U   | U   | --  | 46,1% / high risk of bias |
| Spanemberg et al., 2015 | √   | U   | √   | N/A | U   | --  | √   | N/A | √   | U   | U   | U   | 30,7% / high risk of bias |
| Valenzuela, Lopez Jornet, 2016 | √   | √   | U   | N/A | --  | U   | N/A | √   | √   | √   |   | √   | 53,8% / medium risk of bias |
| Sugaya et al., 2016 | √   | √   | U   | √   | √   | U   | N/A | √   | U   | N/A | N/A | 53,8% / medium risk of bias |
| Spanemberg et al., 2019 | √   | N/A | U   | √   | √   | N/A | √   | N/A | √   | U   | U   | U   | 61,5% / medium risk of bias |
| Bardellini et al., 2019 | √   | √   | √   | √   | √   | N/A | √   | N/A | √   | √   | U   | U   | 76,9% / low risk of bias |
| Skrinjar et al., 2020 | √   | N/A | √   | √   | N/A | N/A | √   | U   | N/A | √   | √   | U   | 53,8% / medium risk of bias |
| Pedro et al., 2020 | √   | √   | √   | √   | √   | U   | √   | N/A | √   | √   | U   | U   | 76,9% / low risk of bias |

Legend: Q.1 - Was true randomization used for assignment of participants to treatment groups?; Q.2 - Was allocation to treatment groups concealed?; Q.3 - Were treatment groups similar at the baseline?; Q.4 - Were participants blind to treatment assignment?; Q.5 - Were those delivering treatment blind to treatment assignment?; Q.6 - Were outcomes assessors blind to treatment assignment?; Q.7 - Were treatment groups treated equally?; Q.8 - Was follow up adequate described and analysed?; Q.9 - Were participants analysed in the groups to which they were randomized?; Q.10 - Were outcomes measured in a reliable way?; Q.11 - Was appropriate statistical analysis used?; Q.12 - Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial? / √ - Yes; -- - No; N/A - Uncertain; N/A - Not applicable.

Sugaya et al. [2016] (14) presented the VAS values on average differently from other studies. They individually reported the participants by received sessions and categorized the values by percentage. It was considered: 0- no burning sensation (0%); 1- excellent reduction in the burning sensation (1–25%); 2- good decrease in the burning sensation (26-50%); 3- regular decrease in the burning sensation (51-75%); 4- burning sensation unchanged (76-100%); 5- the burning sensation worsened (> 100%). The control group started the first session with an average of 52%, in the regular category. In the fourth session, it presented 31% - a good burning sensation. The intervention group, in turn, had an average of 49% in its first session - good burning sensation and ended with 18% - excellent burning sensation.

Bardellini et al. [2019] (21), presented the values of statistical significance, without presenting the average values of VAS in a table. According to the authors, before the sessions, the EVA score was similar in both groups (p= 0.75). After the 5th fifth session, there was a reduction in the average VAS, but without a statistically significant difference between groups (p= 0.6232). At the end of therapy, patients treated with LLLT showed a significant decrease in symptoms (p= 0.0008), maintained at follow-up the day after the last session (p= 0.0005). The places of application of laser therapy varied in the studies. All irradiated areas where the participants reported the symptoms of pain and burning sensation. Four studies did not report the exact locations of application (12,14,21,22). Two studies (13,14) reported that the application was on the oral mucosa, without describing the locations.

Arbabi-Kalati , Bakhshani and Rasti [2015] (11) irradiated ten areas of the oral mucosa - two areas on the oral mucosa on each side, two on the tongue, two on the floor of the mouth, one area on the soft palate and one on the hard palate. Spanemberg et al. [2015] (12) illuminated seventeen points on the tongue (three on the apex, four on the side and ten on the back), eight points on the oral mucosa, five on the lip mucosa, eight points on the hard palate, three points on the soft palate and gums. Spanemberg et al. [2019] (20) used fourteen points on the tongue (three on the tip, four on the lateral edge, ten on the dorsal surface), eight points on the oral mucosa, five on the lip mucosa, eight on the hard palate, three on the soft palate and three points on the gum. Pedro et al. [2020] (19) irradiated four quadrants of the buccal mucosa - four on each lip mucosa, six points on each of the two buccal mucosa, six on the hard palate, four on each lateral edge of the tongue, six on the back of the tongue and four sublingual points.
| Author/Year | Before | Follow-up | After | Efficacy of LLLT on BMS |
|-------------|--------|-----------|-------|------------------------|
| Arbabi-Kalati et al., 2015 | CG: 8.2 | NR | 3.6 | LLLT can decrease the intensity of symptoms in BMS. |
| | LG: 8 | | 8 | |
| | 8 weeks follow-up | | | |
| | LG inf 1: 8.20* | 3.75 | 3.20* | |
| | LG inf 2: 8* | 2.90 | 3* | |
| | RLV: 8.16* | 4.42 | 4.32* | |
| | CG: 9* | 6.47 | 6.05 | |
| Spanemberg et al., 2015 | 2 weeks after | | | LLLT reduced the symptoms of BMS. |
| | NG inf 1: 7,56 | 6.56 | 6,38 | |
| | LG inf 2: 8,38 | 7.44 | 7.06 | |
| | CG: 7,83 | 7,83 | 7,65 | |
| Valenzuela, Lopez Jornet, 2016 | NR | 90 days after the last irradiation | NR | The application of LLLT slightly reduced symptoms in patients with BMS. |
| | LG: 9 | 4,7 | 5,5 | |
| | CG: 8,7 | 5,1 | 6,3 | |
| Sugaya et al., 2016 | 2-months follow-up | | | LLLT is just as beneficial for patients with BMS as placebo treatment. |
| | LG: 5,5* | | 4* | |
| | CG: 5* | | 3* | |
| | NR | | 2 sessions per week for 2 consecutive weeks. | |
| | NR | | 1 session per week for 10 weeks. | |
| | 30 days follow-up | | | The positive results support the choice of LLLT for the treatment of symptoms of BMS. Further RCT studies are needed to define device-specific parameters and protocols to be applied. |
| Bardellini et al., 2019 | LG: 6,8* | 3,9 | 3,4* | LLLT can be useful for reducing burning symptoms. Further research with larger samples is needed to clarify whether the positive results are attributed to the effectiveness of LLLT or the placebo effect. |
| | CG: 7,1* | 7,6 | 7,6* | |
| | 4-months follow-up | | | LLLT appears to be effective in reducing pain in patients with SAB and is a useful treatment that should be included in the management protocols with the pharmacological and psychological. Studies with a greater number of patients and sessions and long-term follow-up will be necessary to evaluate the possibility of applying it periodically. |

Legend: LG- laser group; LG inf: laser group infrared; RLG: red laser group; CG: control group; NR: not reported; BMS: Burning Mouth Syndrome; LLLT: Low level light laser therapy; * p<0.05.
Discussion

The therapy low laser intensity is still considered a new alternative in need of greater understanding of its mechanism of action through high-quality studies with larger sample sizes and longer periods of follow-up (23), although there are controversies about the real effectiveness of this therapy.

The sample of this review was variable regarding the number of participants. The majority was women with an average age that corresponds to the post-menopausal age group. As it affects women, at this stage of life, who may have hormonal instability, the hypothesis of hormonal participation as a cause of BMS is supported. This can be considered a triggering factor in the development and progression of the pathology, but the definitive relationship between BMS and hormonal changes is not yet established (24).

Regarding the wavelength, the red and infra-red spectra (between 390 to 1100 nm) offer stimulating interactions with the biological tissue (15). The studies in this review used wavelengths ranging from 630 to 970 nm. The lower wavelengths induce stimulating effects, while the higher levels provide inhibitory effects (23). A small stimulus of the therapy LLLT may not have a biological effect, while large stimulus may cause inhibitory or cytotoxic effects, by the production of excessive reactive oxygen species excessive that can inhibit production of mitochondrial energy and generate apoptosis (25).

In LLLT, it is not allowed to illuminate the same area with different wavelengths due to the inhibitory action (9). Bardellini et al. [2019] used different wavelengths and frequencies in their applications, which can generate interferences and inhibitory effects (21).

Energy (J) and dose or fluency (J/cm²) often not reported in studies, however, the absence of this information does not prevent the guarantee of an effective laser therapy (9). The laser dose is not shown as a single parameter, but as a set of physical parameters, including power density, creep, radiated effective area, beam intensity profile, duration of exposure, length of length wave or wavelength distribution, total number of exposures and the time between exposures and total fluency (9).

Among the parameters mentioned above, a systematic review pointed out that the fluency or dose of energy should be in the range of 0.5 to 8 J/cm² because it can reduce inflammation and accelerate wound healing (26). Most of the studies analyzed, in this review, used energy fluency higher than recommended by the literature. Two studies far exceeded these values: In Spanemberg et al. [2015] (12), Valenzuela and Lopez-Jornet [2016] (13), no differences were observed before and after treatment on the VAS scale. Six of the eight studies analyzed used continuous waves in the treatment (12-14,19-21). The laser of continuous wave may provide unwanted effects, especially with regard to thermal losses; the lasers super pulsed are capable of acting in a therapeutic manner with deep penetration and shorter periods of treatment, without undesirable these effects (15).

Pulsed lasers provide additional benefits related to pulse attenuation intervals after activation times and require less tissue heating (15). Although the literature theoretically discusses this information, in practice, the continuous wave can work without causing heating in the tissues, since studies of this sample have shown improvement in the symptoms of pain and burning through the average values of the VAS scale.

The time of application is the same for different cell types and is between 100 and 300 seconds (27). Most of the studies in this review did not detail the total exposure time of the tissue to irradiation. Instead, they showed time irradiated by point. One of the two studies that reported the total time exceeded the recommended: they radiated for 381 seconds (22). One area should not be irradiated for more than five minutes and the total treatment time (including all areas) should not exceed twenty minutes (9).

LLLT has an analgesic effect; however, the application must be successive, continuous and in several sessions (8). Six of the eight studies carried out 8 to 10 sessions. Two studies followed the therapy with only 4 sessions (13,14). Both had little difference in the VAS scale score at the end of treatment. Thus, the importance of longer follow-ups is suggested.

It was observed that only the study by Sugaya et al. [2016] (14) reported all the parameters used in the laser application. The others failed to present important data that prevent the in-depth analysis of the functionality of the therapy in relation to the presented outcome.

Seven studies in the sample reported outcomes that point to the effectiveness of low-level laser therapy, with reduced pain and burning sensation in the treated participants; three of them demonstrated statistical significance between the groups (12,19,22).

The therapy the laser low level is described as having minimal side effect and presents a reduction of symptoms in BMS. Some and clinical trials have reported decreased pain and burning sensation in BMS after treatment with LLLT [11-13,19,20]. Skrinjar et al. [2020] (22) further emphasized that the available results make it impossible to clarify whether the positive results are attributed to the effectiveness of LLLT or the placebo effect.

To understand the role of laser in BMS, the pathophysiology of this condition must be highlighted. There is some evidence pointing to the influence of local inflammatory processes in the oral cavity and systemic in association with the pathophysiology of BMS. According to Barry et al. [2018] (28), pro-inflammatory cytokines are generally linked to nociceptive signaling and are
elevated in disorders involving neuropathic pain. This study found elevated plasma levels of the pro-inflammatory cytokine IL-8 in patients with BMS, when compared to plasma from healthy volunteers, and this increase correlated with levels of pain in the oral cavity and depressive symptoms (28).

Another study proved the increased and statistically significant concentration of cytokines IL-2 and IL-6 in all saliva samples from participants with BMS, when compared to healthy individuals (29). Ribarić et al. [2013] (30) found results that, in addition to demonstrating an increase in pro-inflammatory cytokines TNF-α and IL-6 in participants with BMS, found a significant reduction in the salivary levels of these cytokines after treatment with red LLLT for four weeks. Finally, Trel dal et al. [2019] (31) tested a local anesthetic lozenge (bupivacaine) on people with BMS, and assessed inflammation in blood plasma and saliva. The group that did not receive the lozenge tended to have high levels of IL-6, IL-8, IL-17, IL-23 and TNF-α in the plasma, compared to the group that was treated.

Taken together, these results show that inflamed tissues produce a greater amount of reactive oxygen species - a by-product of inflammation - that compromise the production of ATP in cells. The production of nitric oxide (NO) in the mitochondria in cases of injury, such as inflammation, can inhibit the mitochondrial airways, as the NO is reversibly bound to cytochrome c oxidase, an essential enzyme in this airway. The low-intensity laser, in turn, can reverse this binding of NO with cytochrome c oxidase by changing the redox potential of the cell, allowing it to produce ATP and accelerate the process of repairing the inflammatory reaction, improving the symptomatic condition from BMS (15).

A limitation of this systematic review, it can be noted that the studies showed heterogeneity in the application protocols therapy to laser; in addition, there were inconsistencies in the report of the average score of the VAS scale, which hindered the in-depth analysis of the results, limiting the meta-analysis of the data. New well-conducted and standardized clinical trials should be planned using ideal parameters based on the latest available evidence and analysis of the limitations of published clinical trials, with the purpose of controlling bias and better understanding of laser therapy in BMS.

Conclusions
In this review, could be suggested that laser therapy might be effective in treating an alternative BMS. The sample consisted of women with an average age of 60.89 years, a period that corresponds to post-menopause. The most frequent symptoms were pain and a burning sensation, felt mainly in the oral mucosa and tongue. The scores on the VAS scale in three studies were lower in the laser-treated group. BMS is still a clinical condition under investigation and an understanding of its pathophysiology is essential for planning treatments that really work, without confounding effects. Other randomized trials should consider protocols well established laser therapy.

References
1. Klein B, Thopay JR, Rossi SS, Ciarrocca K. Burning Mouth Syndrome. Orofacial. Dermatol Clin. 2020;38:477-83.
2. Bender SD. Burning Mouth Syndrome. Dent Clin North Am. 2018;62:585-96.
3. Zakrzewska J, Buchanan JAG. Burning mouth syndrome. BMJ Clin Evid. 2015;1:1-11.
4. Jääskeläinen SK, Woda A. Burning mouth syndrome. Cephalalgia. 2017;37:627-47.
5. Feller L, Fourie J, Bouckaert M, Khammisa RAG, Ballyram R, Ballyram J. Burning Mouth Syndrome: Aetiopathogenesis and Principles of Management. Pain Res Manag. 2017;18:1-6.
6. Salerno C, Stasio DD, Petruzzii M, Lauritano D, Gentile E, Guida A, et al. An overview of burning mouth syndrome. Front Biosci. 2016;8:213-18.
7. Huang YY, Chen ACH, Carroll JD, Hamblin MR. Biphasic Dose Response in Low Level Light Therapy. Dose Response. 2009;7:358-83.
8. Pandeshwar P, Roa MD, Das R, Shastry SP, Kaull R, Srinivasreddy MB. Photobiomodulation in oral medicine: a review. J Invest Clin Dent. 2016;7:114-26.
9. Moskvin SV. Low-Level Laser Therapy in Russia: History, Science and Practice. J Lasers Med Sci. 2017;8:56-65.
10. Hourred NN, Masha RT, Abrahamse H. Low-Intensity Laser Irradiation at 660 nm Stimulates Cytochrome c Oxidase in Stressed Fibroblast Cells. Lasers Surg Med. 2012;44:1-6.
11. Arbabi-Kalati F, Bakhshani NM, Rasti M. Evaluation of the efficacy of low-level laser in improving the symptoms of burning mouth syndrome. J Clin Exp Dent. 2015;7:524-27.
12. Spanemberg JC, López JL, Figueiredo MAZ, Cherubini K, Salum FG. Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: a randomized, controlled trial. J Biomed Opt. 2015;20:0980011-17.
13. Valenzuela S, Lopez-Jornet P. Effects of low-level laser therapy on burning mouth syndrome. J Oral Rehabil. 2016;44:125-32.
14. Sugaya NN, Silva EFP, Kato IT, Prates R, Gallo CB, Pellegrini VD. Low Intensity laser therapy in patients with burning mouth syndrome: a randomized, placebo-controlled study. Braz Oral Res. 2016;30:1-9.
15. Musstaf RA, Jenkins DFL, Jha AN. Assessing the impact of low level laser therapy (LLLT) on biological systems: a review. Int J Radiat Biol. 2019;95:120-43.
16. Moher D, Liberati A, Tetzlaff J, Douglas G, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6:1-7.
17. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:1-9.
18. Joanna Briggs Institute [Internet]. Critical Appraisal tools for use in JBI Systematic Reviews: Checklist for Randomized Controlled Trials. (2017). cited 2019 Mar 20. Available from: https://joannabriggs.org/critical-appraisal-tools
19. Pedro M, López-Pintor RM, Casaña E, Hernández G. Effects of photobiomodulation with low-level laser therapy in burning mouth syndrome: A randomized clinical trial. Oral Dis. 2020;26:1764-76.
20. Spanemberg JC, Egea JJS, Campillo ERR, Salas EJ, Salum FG, López-López J. Low-level laser therapy in patients with Burning Mouth Syndrome: A double-blind, randomized, controlled clinical trial. J Clin Exp Dent. 2019;11:162-69.
21. Bardellini E, Amadori F, Conte G, Majorana A. Efficacy of the photobiomodulation therapy in the treatment of the burning mouth syndrome. Med Oral Patol Oral Cir Bucal. 2019;24:787-91.
22. Skrinjar I, Brzak BL, Vidrinski V, Boras VV, Rogulić AA, Pucelj B. Salivary Cortisol Levels and Burning Symptoms in Patients with Burning Mouth Syndrome before and after Low Level Laser Therapy: a Double Blind Controlled Randomized Clinical Trial. Acta Stomatol Croat. 2020;54:44-50.
23. Nadhreen AA, Alamoush NM, Elkhodary HM. Low level Laser Therapy in Dentistry: Extra oral Applications. Niger J Clin Pract. 2019;22:1313-18.
24. Kim M, Kho H. Understanding of Burning Mouth Syndrome Based on Psychological Aspects. Chin J Dent Res. 2018;21:9-19.
25. Petrellis MC, Frigo L, Marcos RL, Pallotta RC, Carvalho MHC, Muscarà MN, et al. Laser photobiomodulation of pro-inflammatory mediators on Walker Tumor 256 induced rats. J Photochem Photobiol B. 2017;177:69-75.
26. Al-Maweri SA, Javed F, Kalakonda B, Alaizari NA, Soneidar WA, Al-Akwa A. Efficacy of Low Level Laser Therapy in the Treatment of Burning Mouth Syndrome: A Systematic Review. Photodiagnostics Phototherapy. 2016;16:1-22.
27. Moskvin SV. Only lasers can be used for low level laser therapy. Biomedicine. 2017;7:4-11.
28. Barry A, O’Halloran KDO, McKenna JP, McCreary C, Downer EJ. Plasma IL-8 signature correlates with pain and depressive symptomatology in patients with Burning Mouth Syndrome: results from a pilot study. J Oral Pathol Med. 2018;47:158-65.
29. Simcic D, Ribaric SP, Grzic R, Horvat J, Brumini G, Mušvic-Urek M. Detection of Salivary Interleukin 2 and Interleukin 6 in Patients With Burning Mouth Syndrome. Mediators Inflamm. 2006;20:1-4.
30. Ribaric SP, Kajiku L, Brumini G, Urek MM, Antonié R, Kuis D, et al. Proinflammatory cytokine levels in saliva in patients with burning mouth syndrome before and after treatment with low-level laser therapy. Lasers Med Sci. 2013;28:297-301.
31. Tredal C, Petersen J, Mogensen S, Therkildsen C, Jacobsen J, Andersen O, et al. Characterization of burning mouth syndrome profiles based on response to a local anaesthetic lozenge. Oral Dis. 2020;26:656-69.

Acknowledgements
Support Foundation for Research and Technological Innovation of the State of Sergipe- FAPITEC-SE. This study was financed in part by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil) - finance code 001. We are also thankful for the support of CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brasil) – finance code 307808/2018-1.

Funding
None declared.

Conflict of interest
The authors have no conflicts of interest to report.

Authors contributions
Ana Liz Pereira de Matos: (x) In the conception OR design of the work; OR acquisition, analysis, OR interpretation of research data; (x) In writing OR critical review with intellectual contribution; (x) In the final approval of the version for publication.
Luiz Renato Paranhos: (x) In the conception OR design of the work; OR acquisition, analysis, OR interpretation of research data; (x) In writing OR critical review with intellectual contribution; (x) In the final approval of the version for publication.
Ingrede Tatiane Serafim Santana: ( ) In the conception OR design of the work; OR acquisition, analysis, OR interpretation of research data; (x) In writing OR critical review with intellectual contribution; (x) In the final approval of the version for publication.
Felipe Rodrigues de Matos: (x) In the conception OR design of the work; OR acquisition, analysis, OR interpretation of research data; (x) In writing OR critical review with intellectual contribution; (x) In the final approval of the version for publication.